Intensity-modulated radiotherapy of the prostate: Dynamic ADC monitoring by DWI at 3.0 T

Radiotherapy and Oncology

Volumn 113, Issue 1, 2014, Pages 115-120

  Decker, Georges ^a   Mürtz, Petra ^a   Gieseke, Jürgen ^b   Träber, Frank ^a   Block, Wolfgang ^a   Sprinkart, Alois M ^a   Leitzen, Christina ^a   Buchstab, Timo ^a   Lütter, Christiana ^a   Schüller, Heinrich ^a   Schild, Hans H ^a   Willinek, Winfried A ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Phillips Healthcare   (Netherlands)

Author keywords

3 T; DWI; IMRT; PCa

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; GLUTEUS MAXIMUS MUSCLE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; TREATMENT RESPONSE; VERY ELDERLY; BIOPSY; CANCER GRADING; EVALUATION STUDY; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BIOPSY; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 84922702052     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.07.016     Document Type: Article

References (29)

1. Hsu C-Y, Shen Y-C, Yu C-W, et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol 2011; 55: 858-65.
2. Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 2005; 91: 1-10.
3. Chenevert TL, Meyer CR, Moffat BA, et al. Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging 2002; 1: 336-43.
4. Seierstad T, Røe K, Olsen DR. Noninvasive monitoring of radiation-induced treatment response using proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging in a colorectal tumor model. Radiother Oncol J Eur Soc Ther Radiol Oncol 2007; 85: 187-94.
5. Song I, Kim CK, Park BK, Park W. Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. Am J Roentgenol 2010; 194: W477-82.
6. Park SY, Kim CK, Park BK, et al. Early changes in apparent diffusion coefficient from diffusion-weighted MR imaging during radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2012; 83: 749-55.
7. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22: 746-57.
8. Le Bihan D. Intravoxel incoherent motion imaging using steady-state free precession. Magn Reson Med 1988; 7: 346-51.
9. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168: 497-505.
10. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986; 161: 401-7.
11. Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005; 21: 258-62.
12. Ginat DT, Mangla R, Yeaney G, Johnson M, Ekholm S. Diffusion-weighted imaging for differentiating benign from malignant skull lesions and correlation with cell density. Am J Roentgenol 2012; 198: W597-601.
13. Rechichi G, Galimberti S, Signorelli M, et al. Endometrial cancer: correlation of apparent diffusion coefficient with tumor grade, depth of myometrial invasion, and presence of lymph node metastases. Am J Roentgenol 2011; 197: 256-62.
14. Wang XZ, Wang B, Gao ZQ, et al. Diffusion-weighted imaging of prostate cancer: correlation between apparent diffusion coefficient values and tumor proliferation. J Magn Reson Imaging 2009; 29: 1360-6.
15. Zelhof B, Pickles M, Liney G, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 2009; 103: 883-8.
16. Hambrock T, Somford DM, Huisman HJ, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate Cancer. Radiology 2011; 259: 453-61.
17. Padhani AR, Khan AA. Diffusion-weighted (DW) and dynamic contrastenhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. Target Oncol 2010; 5: 39-52.
18. Tamada T, Sone T, Jo Y, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 2008; 28: 720-6.
19. Turkbey B, Shah VP, Pang Y, et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 2011; 258: 488-95.
20. Gibbs P, Pickles MD, Turnbull LW. Repeatability of echo-planar-based diffusion measurements of the human prostate at 3 T. Magn Reson Imaging 2007; 25: 1423-9.
21. Ross B, Chenevert T, Kim B, Ben-Joseph O. Magnetic resonance imaging and spectroscopy: application to experimental neurooncology. J Magn Reson Biol Med 1994: 89-106.
22. Li SP, Padhani AR. Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging 2012; 35: 745-63.
23. Takayama Y, Kishimoto R, Hanaoka S, et al. ADC value and diffusion tensor imaging of prostate cancer: changes in carbon-ion radiotherapy. J Magn Reson Imaging 2008; 27: 1331-5.
24. Balcer-Kubiczek EK. Apoptosis in radiation therapy: a double-edged sword. Exp Oncol 2012; 34: 277-85.
25. He Z, Zhang Y, Mehta SK, Pierson DL, Wu H, Rohde LH. Expression profile of apoptosis related genes and radio-sensitivity of prostate cancer cells. J Radiat Res (Tokyo) 2011; 52: 743-51.
26. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 2005; 102: 5524-9.
27. Barnett GC, West CML, Dunning AM, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009; 9: 134-42.
28. Vicini FA, Vargas C, Abner A, Kestin L, Horwitz E, Martinez A. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol 2005; 173: 1456-62.
29. Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 1997; 44: 213-21.